WO2019035565A3 - 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 - Google Patents

안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 Download PDF

Info

Publication number
WO2019035565A3
WO2019035565A3 PCT/KR2018/008047 KR2018008047W WO2019035565A3 WO 2019035565 A3 WO2019035565 A3 WO 2019035565A3 KR 2018008047 W KR2018008047 W KR 2018008047W WO 2019035565 A3 WO2019035565 A3 WO 2019035565A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
cancer patient
screening method
androgen receptor
patient screening
Prior art date
Application number
PCT/KR2018/008047
Other languages
English (en)
French (fr)
Other versions
WO2019035565A2 (ko
Inventor
전병희
Original Assignee
주식회사 싸이토젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 싸이토젠 filed Critical 주식회사 싸이토젠
Priority to JP2020504367A priority Critical patent/JP7040816B2/ja
Priority to CN201880048130.9A priority patent/CN110945359B/zh
Priority to US16/631,336 priority patent/US11789023B2/en
Priority to EP18845984.6A priority patent/EP3671214A4/en
Publication of WO2019035565A2 publication Critical patent/WO2019035565A2/ko
Publication of WO2019035565A3 publication Critical patent/WO2019035565A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N2021/1765—Method using an image detector and processing of image signal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

본 발명의 일실시예에 따르면, 혈중 순환 암세포 및 AR변이체의 광학 이미지 분석을 통해서 전립선암환자에 AR 표적 치료가 적용되는지 여부를 분석할 수 있는 전립선암환자 스크리닝 방법을 제공한다.
PCT/KR2018/008047 2017-08-18 2018-07-17 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법 WO2019035565A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020504367A JP7040816B2 (ja) 2017-08-18 2018-07-17 アンドロゲン受容体変異体ベースの前立腺癌患者スクリーニング方法
CN201880048130.9A CN110945359B (zh) 2017-08-18 2018-07-17 基于雄激素受体的变异体的前列腺癌患者筛查方法
US16/631,336 US11789023B2 (en) 2017-08-18 2018-07-17 Androgen receptor variant-based prostate cancer patient screening method
EP18845984.6A EP3671214A4 (en) 2017-08-18 2018-07-17 METHOD FOR SCREENING PROSTATE CANCER PATIENTS BASED ON ANDROGEN RECEPTOR VARIANTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0104477 2017-08-18
KR1020170104477A KR101926117B1 (ko) 2017-08-18 2017-08-18 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법

Publications (2)

Publication Number Publication Date
WO2019035565A2 WO2019035565A2 (ko) 2019-02-21
WO2019035565A3 true WO2019035565A3 (ko) 2019-04-11

Family

ID=64671535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008047 WO2019035565A2 (ko) 2017-08-18 2018-07-17 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법

Country Status (6)

Country Link
US (1) US11789023B2 (ko)
EP (1) EP3671214A4 (ko)
JP (1) JP7040816B2 (ko)
KR (1) KR101926117B1 (ko)
CN (1) CN110945359B (ko)
WO (1) WO2019035565A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101992604B1 (ko) * 2017-09-05 2019-06-25 주식회사 싸이토젠 전립선특이 막항원 기반 전립선암환자 스크리닝 방법
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
US11995833B2 (en) * 2020-07-31 2024-05-28 The Joan and Irwin Jacobs Technion-Cornell Institute System and method for on-phase microscopy
WO2022216113A1 (ko) * 2021-04-09 2022-10-13 주식회사 싸이토젠 면역관문억제제를 이용한 암 치료방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007447A (ko) * 2005-05-02 2008-01-21 사이틱 코포레이션 자동 이미징 프로세스 및 장치
JP2009525468A (ja) * 2006-01-30 2009-07-09 ザ・スクリプス・リサーチ・インステイチユート 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
US20120148142A1 (en) * 1999-01-25 2012-06-14 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
KR20170038724A (ko) * 2015-09-30 2017-04-07 주식회사 싸이토젠 광학적 세포 식별방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529704A (ja) 1998-10-29 2002-09-10 セル ワークス インコーポレイテッド 単一細胞の複数マーカー特徴付け
FR2824144B1 (fr) 2001-04-30 2004-09-17 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
JP5704590B2 (ja) 2010-02-05 2015-04-22 国立大学法人東京農工大学 サイズ選択マイクロキャビティアレイを用いた循環腫瘍細胞の検出
US20140154703A1 (en) 2011-01-06 2014-06-05 Alison Skelley Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size
KR101279918B1 (ko) 2011-05-27 2013-07-01 한국과학기술연구원 종양세포 검출장치 및 종양세포 검출방법
CA2856405C (en) 2011-11-21 2021-05-25 Creatv Microtech, Inc. Polymer microfiltration devices, methods of manufacturing the same and the uses of the microfiltration devices
JP6208473B2 (ja) 2012-06-20 2017-10-04 アークレイ株式会社 血液成分を含む試料の処理方法
WO2014082096A1 (en) * 2012-11-26 2014-05-30 The Trustees Of Columbia University In The City Of New York Method for culture of human and mouse prostate organoids and uses thereof
WO2014172340A1 (en) * 2013-04-15 2014-10-23 Georgetown University Immortalization of circulating tumor cells and methods of use
WO2015048740A1 (en) * 2013-09-30 2015-04-02 The Scripps Research Institute Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients
US20160011198A1 (en) 2014-01-27 2016-01-14 Epic Sciences, Inc. Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
JP2016052300A (ja) 2014-09-03 2016-04-14 日立化成株式会社 生体物質捕獲システム
JP6841772B2 (ja) 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3304074B1 (en) 2015-05-26 2019-10-16 Creatv Microtech, Inc. Use of circulating tumor cell mitotic index in cancer stratification and diagnostics
US20190285636A1 (en) 2015-09-25 2019-09-19 Epic Sciences, Inc. ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
JP2017108738A (ja) 2015-12-15 2017-06-22 東ソー株式会社 細胞検出装置および細胞回収装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148142A1 (en) * 1999-01-25 2012-06-14 Amnis Corporation Detection of circulating tumor cells using imaging flow cytometry
KR20080007447A (ko) * 2005-05-02 2008-01-21 사이틱 코포레이션 자동 이미징 프로세스 및 장치
JP2009525468A (ja) * 2006-01-30 2009-07-09 ザ・スクリプス・リサーチ・インステイチユート 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
KR20170038724A (ko) * 2015-09-30 2017-04-07 주식회사 싸이토젠 광학적 세포 식별방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MA, YAFENG: "Droplet Digital PCR Based Androgen Receptor Variant 7 ( AR -V7) Detection from Prostate Cancer Patient Blood Biopsies", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 17, no. 4, 2016, pages 1 - 11, XP055589963 *
REYES, EDWIN E, QUANTITATIVE CHARACTERIZATION OF ANDROGEN RECEPTOR PROTEIN EXPRESSION AND CELLULAR LOCALIZATION IN CIRCULATING TUMOR CELLS FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, vol. 12, 2014, pages 1 - 15, XP021206180 *

Also Published As

Publication number Publication date
EP3671214A2 (en) 2020-06-24
JP7040816B2 (ja) 2022-03-23
WO2019035565A2 (ko) 2019-02-21
US11789023B2 (en) 2023-10-17
KR101926117B1 (ko) 2018-12-06
CN110945359A (zh) 2020-03-31
CN110945359B (zh) 2024-01-05
US20200225238A1 (en) 2020-07-16
JP2020529023A (ja) 2020-10-01
EP3671214A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
WO2019035565A3 (ko) 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
CY1123652T1 (el) Πολλαπλολειτουργικα μαγνητο-πολυμερικα νανοσυστηματα για ταχεια στοχευση, απομονωση, ανιχνευση και ταυτοχρονη απεικονιση των κυκλοφορουντων κυτταρων ογκων
MX2019011148A (es) Metodos de tratamiento.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
EP3891294A4 (en) METHODS OF TREATMENT FOR CASTRATION-RESISTANT AND CASTRATION-SENSITIVE PROSTATE CANCER
EA201892485A1 (ru) Способ получения соединения диарилтиогидантоина
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
EP3490677A4 (en) LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
IL276748A (en) Methods for the detection and treatment of prostate cancer
EP3568132A4 (en) MODULATION BY LASOFOXIFEN OF EESTROGENIC SIGNALS OF MEMBRANARY ORIGIN AND METHODS FOR THE TREATMENT OF TUMORS
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
EP3775167A4 (en) METHODS OF TREATING CANCER USING TUMOR ANTIGEN SPECIFIC T LYMPHOCYTES
MX2019001635A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
EP3565560A4 (en) PREDICTIVE AND DIAGNOSTIC PROCEDURES FOR PROSTATE CANCER
MX2019003603A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
TW201613587A (en) Medical treatments based on anamorelin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18845984

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020504367

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018845984

Country of ref document: EP

Effective date: 20200318